Medicines | Horizonscan geneesmiddelen

Durvalumab

Neo-adjuvant durvalumab met chemotherapie en adjuvant durvalumab voor behandeling in patiënten met spier invasieve blaaskanker. ^IND Unresectable locally advanced or metastatic urothelial cancer in combination with tremelimumab and chemotherapy ^IND

Enfortumab vedotin ^IND Erdafitinib Inbakicept Nivolumab ^IND

Dabrafenib / trametinib

Abemaciclib ^IND Atezolizumab ^IND Balixafortide Capivasertib Elacestrant Neratinib ^IND Olaparib ^IND Paclitaxel Palbociclib ^IND Pembrolizumab ^IND

Sacituzumab govitecan

For adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for advanced disease Extension of indication to include treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. ^IND

Tesetaxel

Trastuzumab deruxtecan

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens. Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2‑low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy ^IND Extension of indication for Enhertu to include treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. ^IND Extension of indication to include treatment of HER2-low/ultra-low hormone receptor positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting. ^IND

Trastuzumab duocarmazine

Cadonilimab Cemiplimab ^IND Lifileucel

Eflornithine / sulindac Fruquintinib Trifluridine / tipiracil

Atezolizumab ^IND Leukocyte interleukin Tislelizumab ^IND

Atezolizumab ^IND Belzutifan Ilixadencel Lenvatinib ^IND

Pembrolizumab

Extension of indication for Keytruda to include in combination with lenvatinib first line treatment of adults with advanced renal cell carcinoma (RCC). ^IND Keytruda as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions. ^IND

Atezolizumab ^IND

Durvalumab

Durvalumab (+/- bevacizumab) in combinatie met TACE in patiënten met locoregionale HCC. ^IND Imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). ^IND

Tremelimumab

Adagrasib

Atezolizumab

Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK‑positive NSCLC ^IND Atezolizumab subcutaneous in patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC). ^IND Neoadjuvant atezolizumab with chemotherapy in patients with resectable stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC). ^IND

Aumolertinib (mesilate) Cabozantinib ^IND Capmatinib

Cemiplimab

Libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC. ^IND LIBTAYO in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with NSCLC expressing PD-L1 (in ≥ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC. ^IND

Domvanalimab

Durvalumab

Imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations. ^IND 1L advanced NSCLC ^IND Completely resected NSCLC ^IND Lokaal gevorderd, niet-resectabel NSCLC (stadium III) ^IND Limited stage small cell lung cancer (LS-SCLC) following concurrent platinum-based chemotherapy and radiation therapy in combination with Tremelimumab. ^IND

Ensartinib Lenvatinib ^IND Nintedanib ^G Nivolumab ^IND OSE-2101

Osimertinib

Osimertinib with platinum plus pemetrexed chemotherapy as first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. ^IND Stage III unresectable Epidermal Growth Factor Receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) ^IND

Pembrolizumab

Extension of indication to include Keytruda as monotherapy for the adjuvant treatment of adults with Stage IB (T2a ≥ 4 cm), II or IIIA non-small cell lung carcinoma (NSCLC) who have undergone complete resection. ^IND Extension of indication to include in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant, treatment of resectable stage II, IIIA, or IIIB (T3 4N2) non-small cell lung carcinoma in adults. ^IND

Selpercatinib ^IND Serplulimab Sugemalimab

Tislelizumab

2L NSCLC (mono): As monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults 1L non-squamous NSCLC (combi): In combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of locally advanced or metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations 1L squamous NSCLC (combi): In combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of locally advanced or metastatic squamous NSCLC in adults

Toripalimab ^IND Trastuzumab deruxtecan ^IND Tremelimumab

AL102 Afamitresgene autoleucel Durvalumab ^IND Efbemalenograstim alfa Erdafitinib Futibatinib Glucarpidase Ivosidenib Jodium (131I) omburtamab Lenvatinib ^IND Melphalan hydrochloride Nirogacestat

Pembrolizumab

Extension of indication to include pembrolizumab in combination with lenvatinib for the treatment of advanced endometrial carcinoma in adults who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation. ^IND Keytruda as monotherapy is indicated for the treatment of the following MSI‑H or dMMR tumours in adults with: unresectable or metastatic colorectal cancer after previous fluoropyrimidine‑based combination therapy; advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum‑containing therapy in any setting and who are not candidates for curative surgery or radiation; unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. ^IND indication for treatment with pembrolizumab plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma ^IND

Retifanlimab Selinexor ^IND Sodium thiosulfate Tebentafusp

Tislelizumab

2L locally advanced or metastatic ESCC (esophageal squamous-cell carcinoma) 1L locally advanced or metastatic ESCC (esophageal squamous-cell carcinoma)

Toripalimab

Toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma (“NPC”) Toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (“ESCC”)

Dostarlimab

Stage III or IV non mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (collectively referred to as "ovarian cancer") ^IND Extension of indication to include in combination with platinum -containing chemotherapy the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability -high (MSI -H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy ^IND

Mirvetuximab soravtansine Rucaparib ^IND

Atezolizumab ^IND Darolutamide ^IND Degarelix ^G Enzalutamide ^IND Gozetotide Lutetium (177lu) vipivotide tetraxetan Masitinib Niraparib / abirateron

Olaparib

Treatment in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated. ^IND treatment of adults with metastatic castration resistant prostate cancer (mCRPC), with Lynparza in combination with abiraterone and prednisone or prednisolone ^IND

Talazoparib ^IND

Darleukin fibromun Ipilimumab ^IND Lenvatinib ^IND Lifileucel

Nivolumab

Extension of indication to include adolescent patients aged 12 years and older in treatment of advanced (unresectable or metastatic) melanoma (nivolumab monotherapy), treatment of advanced (unresectable or metastatic) melanoma (nivolumab in combination with ipilimumab) and adjuvant treatment of melanoma (nivolumab monotherapy). ^IND Extension of indication to include OPDIVO for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who have undergone complete resection. ^IND

Pembrolizumab ^IND Relatlimab / nivolumab Tavokinogene telseplasmid

Catumaxomab Domvanalimab Nivolumab ^IND

Pembrolizumab

Extension of indication for treatment with pembrolizumab plus trastuzumab in combination with standard of care chemotherapy for adults with HER2 positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma ^IND Extension of indication to include in combination with chemotherapy the first -line treatment of locally advanced unresectable or metastatic HER2 -negative gastric or gastrooesophageal junction adenocarcinoma in adults. ^IND Treatment in the neoadjuvant or adjuvant setting of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma. ^IND

Tislelizumab ^IND Trastuzumab deruxtecan ^IND Zolbetuximab

Selpercatinib

Extension of indication to include the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer in the first-line setting for Retsevmo. ^IND Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC) ^IND

Selpercatinib ^IND

Dasatinib ^IND Ibrutinib ^IND Tagraxofusp

Oncology

Bladder cancer

Durvalumab

Brain cancer

Breast cancer

Sacituzumab govitecan

Trastuzumab deruxtecan

Cervical cancer

Colon cancer

Head and neck cancer

Kidney cancer

Pembrolizumab

Liver cancer

Durvalumab

Lung cancer

Atezolizumab

Cemiplimab

Durvalumab

Osimertinib

Pembrolizumab

Tislelizumab

Oncology other

Pembrolizumab

Tislelizumab

Toripalimab

Ovarian cancer

Dostarlimab

Prostate cancer

Olaparib

Skin cancer

Nivolumab

Stomach cancer

Pembrolizumab

Thyroid cancer

Selpercatinib

Tumour agnostic medication

Unknown

Service

About this site